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Abstract
The use of human albumin is common in hepatology 
since international scientific societies support its 
administration to treat or prevent severe complications 
of cirrhosis, such as the prevention of post-paracentesis 
circulatory dysfunction after large-volume paracentesis 
and renal failure induced by spontaneous bacterial 
peritonitis, and the treatment of hepatorenal syndrome 
in association with vasoconstrictors. However, these 
indications are often disregarded, mainly because the 
high cost of human albumin leads health authorities 
and hospital administrations to restrict its use. On the 
other hand, physicians often prescribe human albumin 
in patients with advanced cirrhosis for indications that 
are not supported by solid scientific evidence and/or are 
still under investigation in clinical trials. 
In order to implement appropriate prescription 
of human albumin and to avoid its futile use, the 
Italian Association for the Study of the Liver (AISF) 
and the Italian Society of Transfusion Medicine and 
Immunohaematology (SIMTI) nominated a panel of 
experts, who reviewed the available clinical literature 
and produced practical clinical recommendations for the 
use of human albumin in patients with cirrhosis.
1. Introduction
The clinical use of human albumin (HA) dates 
back to World War II when it was administered for 
fluid resuscitation. Since then, its administration has 
been extended to many other diseases since physicians 
commonly believe in its efficacy. However, apart from 
some clinical indications for which its use is supported 
by solid scientific evidence, in many other settings the 
efficacy of HA has been disproven by evidence-based 
medicine or is still under debate. 
Hepatology is an area in which the use of HA is 
particularly common, since this treatment is currently 
employed to treat or prevent severe complications of 
cirrhosis. Randomised clinical trials and meta-analyses 
have demonstrated its efficacy in the prevention of 
post-paracentesis circulatory dysfunction (PPCD) 
after large-volume paracentesis and renal failure 
induced by spontaneous bacterial peritonitis (SBP), 
and in the treatment of hepatorenal syndrome (HRS) in 
association with vasoconstrictors. Although endorsed by 
international scientific societies1,2, these indications are 
often disregarded, even in specialised centres, mainly 
because the high cost of HA leads health authorities and 
hospital administrations to restrict its use. On the other 
hand, physicians often prescribe HA in patients with 
advanced cirrhosis for indications that are not supported 
by solid scientific evidence and/or are still under 
investigation in clinical trials. This inappropriate use 
may limit the availability for the patients in whom HA 
administration is supported by solid scientific evidence.
In order to implement appropriate prescription of 
HA and to avoid its futile use, the Italian Association 
for the Study of the Liver (AISF) and the Italian Society 
of Transfusion Medicine and Immunohaematology 
(SIMTI) nominated a panel of experts, who reviewed 
the available clinical literature and produced practical 
clinical recommendations for the use of HA in patients 
with liver cirrhosis. The initial draft was revised by a 
second panel of experts identified by the two scientific 
societies, so that the final version resulted from the 
consensus of the two working groups.
The  l eve l  o f  ev idence  and  s t r eng th  o f 
recommendation were judged according to the Grading 
of Recommendations Assessment Development and 
Evaluation (GRADE) system3. The strength of the 
evidence has been classified into four levels: high (A), 
moderate (B), low (C), and very low (D) quality evidence, 
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while that of the recommendation has been divided into 
two: strong (1) and weak (2) (Table I). Where no clear 
evidence exists, the recommendations are based on the 
consensus advice of the writing committee and the expert 
opinion(s) reported in the literature. 
2. The albumin molecule
2.1 Structure
HA is the main circulating protein in healthy 
individuals (3.5-5 g/dL), accounting for about 50% of the 
plasma proteins. It is a small protein (molecular weight: 
66.5 kDa), consisting of a single chain of 585 amino 
acids organised in three repeated homologues domains 
(I, II, and III), each of which comprises two separate 
sub-domains (A and B). Of the 35 cysteine residues 
of the molecule, 34 are involved in internal disulphide 
bonds which stabilise the spatial conformation of the 
molecule, while the cysteine at position 34 (Cys-34) 
remains free in the reduced form, thus representing the 
major functional site of HA4. 
2.2 Metabolism
HA is synthesised by hepatocytes and released 
into the circulation (about 10-15 grams every day). 
Its synthesis is stimulated by hormonal factors, such 
as insulin, cortisol and growth hormone, while pro-
inflammatory mediators exert an inhibitory effect. 
Once produced, approximately 30-40% circulates in the 
blood stream, while the remaining leaves the vascular 
compartment at a rate of 5% per hour (transcapillary 
escape rate) and returns to it via the lymphatic system; 
the amount that returns to the vascular compartment is 
the same as the amount that leaves it. The circulatory 
half-life of HA is approximately 16-18 hours, while its 
total half-life varies from about 12 to 19 days in healthy 
young adults. HA is mainly degraded by the muscles, 
liver and kidneys, although many other tissues can 
participate in its catabolism4-6.
2.3 Properties
HA is the main modulator of fluid distribution in the 
various compartments of the body accounting for about 
70-80% of the plasma oncotic pressure. Two-thirds of 
the oncotic capacity derives from the direct osmotic 
effect related to its molecular mass and high plasma 
concentration while one-third is the results of the Gibbs-
Donnan effect, due to the negative net charge of the 
molecule that is consequently able to attract positively 
charged molecules (i.e. sodium and, therefore, water) 
into the bloodstream4-6.
HA has many other biological properties that are 
unrelated to the regulation of fluid compartmentalisation 
(Figure 1). Some of these non-oncotic properties 
assume particular importance, such as scavenging and 
detoxification of reactive oxygen and nitrogen species, 
binding and transport of many hydrophobic endogenous 
molecules (e.g., cholesterol, fatty acids, bilirubin, 
thyroxine) and exogenous ones (e.g., drugs, including 
many antibiotics), preservation of the functional integrity 
of the microcirculation (e.g., endothelial stabilisation and 
platelet anti-aggregation), and modulation of the immune 
and inflammatory responses (e.g., binding of endotoxins, 
prostaglandins, and pro-inflammatory cytokines)4,5.
3. Rationale for the use of human albumin in 
liver cirrhosisis
Hypoalbuminaemia is a typical feature of cirrhosis 
and is an independent adverse prognostic factor. Beside 
decreased hepatocyte synthesis, it results from dilution 
of the extracellular fluid protein content due to the total 
plasma volume expansion consequent to renal sodium 
and water retention, from increased catabolism probably 
Table I - Grading evidences and recommendations (adapted from the GRADE system).
Quality of evidence
A - High Further research is very unlikely to change our confidence in the estimate of effect.
• Several high-quality studies with consistent results
• In special cases: one large, high-quality multicentre trial
B - Moderate Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
• One high-quality study
• Several studies with some limitations
C - Low Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
• One or more studies with severe limitations 
D - Very low Any estimate of effect is very uncertain.
Expert opinion
• No direct research evidence
• One or more studies with very severe limitations
Strenght of recommendation
1 - Strong Factors influencing the strength of the recommendation included the quality of evidence, presumed  patient-important outcomes, and cost.
2 - Weak Variability in preferences and values, or more uncertainty: more likely a weak recommendation is warranted.
Recommendation is made with less certainty:  high cost or resource consumption
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accelerated by the damage of the molecule, and from 
the increased trans-capillary escape rate towards the 
extravascular space, at least in patients with refractory 
ascites4,5. 
In addition to quantitative changes, HA undergoes 
structural and functional alterations that are probably 
favoured by the pro-inflammatory and pro-oxidant state 
of advanced cirrhosis6,7. Extensive post-transcriptional 
changes, involving several sites of the molecule, develop 
and increase in parallel with the disease severity7. 
Physiological functions of HA appear to be impaired, 
including the ability to chelate cobalt and binding and 
transport capacities8.
It can, therefore, be hypothesised that, in patients 
with cirrhosis, the global function of HA, resulting from 
both oncotic and non-oncotic properties, is not only 
related to its absolute concentration in the circulation, 
but also to the degree of preservation of its structural 
and functional integrity5-8.
Advanced cirrhosis is characterised by two 
major systemic features: circulatory dysfunction and 
chronic inflammation. These alterations are strictly 
inter-related and cooperate to cause the multi-organ 
dysfunction and failure occurring in end-stage 
cirrhosis (Figure 2)5.
The cardiovascular alterations involve both the 
circulation and the heart9. The dominant haemodynamic 
change is a progressive reduction of effective arterial 
volaemia. Effective hypovolaemia mainly results 
from the fall of systemic vascular resistance, mostly 
in the splanchnic area, due to the increased production 
of vasoactive substances (e.g. nitric oxide, carbon 
monoxide, endocannabinoids), inducing vasodilation 
and hampering the response to vasoconstrictors. This 
evokes the compensatory activation of neuro-humoral 
systems able to promote vasoconstriction and renal 
retention of sodium and water, including the renin-
angiotensin-aldosterone axis (RAA), sympathetic 
nervous system (SNS), and arginine-vasopressin (ADH). 
As a result, from a functional point of view, patients 
with decompensated cirrhosis are hypovolaemic and 
exhibit cardiovascular hyporeactivity, even though their 
cardiac output can be normal or elevated. However, 
a fall in cardiac output, leading to an exacerbation 
of effective hypovolaemia, is observed in the more 
advanced stages of the disease, indicating the occurrence 
of clinically relevant cardiac dysfunction. In the end-
stage of the disease, the extreme effective hypovolaemia 
directly induces a further reduction in the perfusion of 
kidneys and other organs, thus generating ischaemic 
tissue damage until multi-organ failure develops. 
In this pathophysiological scenario, preservation of 
the effective blood volume is a primary goal in the 
management of these patients. 
Patients with decompensated cirrhosis also have a 
chronic state of moderate systemic inflammation, which 
is related to the sustained stimulation of the immune 
system cells activated by the translocation of bacterial 
products (e.g., lipopolysaccharide, bacterial DNA) from 
the intestinal lumen to the circulation due to quantitative 
and qualitative changes in gut microbiota, impairment 
in the intestinal mucosal barrier, increased epithelial 
permeability, and impaired intestinal immunity10. In a 
vicious circle, the cytotoxic agents released during the 
inflammatory process contribute to produce splanchnic 
vasodilation and depress cardiac contractility, thus 
exacerbating circulatory dysfunction10. They can also 
contribute directly to organ dysfunction by inducing 
microvascular coagulation and cell damage10.
While systemic inflammation and oxidative stress 
are steadily moderate in patients with decompensated 
cirrhosis, they become rapidly severe in patients with 
acute-on-chronic liver failure6. Acute-on-chronic liver 
failure is a clinical syndrome characterised by acute 
development of organ failure (of liver, kidneys, brain, 
lungs, coagulation, and circulation) and a short-term, 
high risk of mortality, usually precipitated by bacterial 
infection, acute alcoholic hepatitis or other clinical 
events, even if a specific cause cannot be identified in 
a considerable number of cases11. 
Due to its oncotic and non-oncotic properties, 
HA can exert a beneficial effect at different steps of 
the vicious circle that links circulatory dysfunction, 
inflammatory response, and oxidative stress in patients 
with decompensated cirrhosis. 
4. Clinical use of albumin in cirrhosis
HA is given to patients with advanced cirrhosis with 
the purpose of antagonising the effective hypovolaemia, 
mainly because of its capacity to act as a potent plasma-
expander by increasing cardiac output and refilling the 
dilated arterial vascular compartment, although some 
positive effects on circulatory function and cardiac 
contractility also appear to be mediated by its non-
oncotic properties12,13.
International guidelines currently endorse the use 
of HA to manage clinical complications of cirrhosis 
characterised by extreme effective hypovolaemia: (i) 
prevention of PPCD; (ii) prevention of renal failure 
induced by SBP; and (iii) diagnosis and treatment 
of HRS, in association with vasoconstrictor drugs1,2. 
A consequent assumption is that the presence of 
hypoalbuminaemia should not be a pre-requisite 
for the administration of exogenous HA in these 
conditions. 
Beside these universally accepted and evidence-
based indications, the administration of HA has been 
proposed for other clinical conditions in patients 
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Figure 1 - Oncotic and non-oncotic properties of human albumin. 
 Cys-34: cysteine-34; LPS: lipopolysaccharides: NO: nitric oxide; PG: prostaglandins; TNFα: tumour 
necrosis factor-alpha.
PORTAL HYPERTENSION
SPLANCHNIC
VASODILATION
CARDIAC 
DYSFUNCTION
EFFECTIVE 
HYPOVOLAEMIA
INFLAMMATION
RENAL
DYSFUNCTION
HYPONATRAEMIA
LIVER 
FAILURE
MULTIORGAN
FAILURE
BACTERIAL 
TRANSLOCATION
ASCITES HEPATORENAL
SYNDROME
SUSCEPTIBILITY
TO SHOCK
VASOCONSTRICTORS AND
SODIUM-RETAINING SYSTEMS
ADRENAL
INSUFFICIENCY
HEPATIC
ENCEPHALOPATY
Figure 2 - Major pathophysiological events in advanced liver cirrhosis.
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with cirrhosis. Long-term treatment of ascites not 
responding to diuretic treatment is allowed in Italy by 
the Italian Medicines Agency (AIFA), even if solid 
scientific evidence supporting its use in this context has 
not been published as yet. Treatment of hyponatraemia 
is another example of HA use not based on evidence. 
Other clinical indications currently under investigation 
in patients with cirrhosis are treatment of bacterial 
infections other than SBP, hepatic encephalopathy, and 
septic shock (Table II). 
AISF-SIMTI recommendations 
- In the specific setting of patients with advanced 
cirrhosis, the presence of hypoalbuminaemia should 
not be the guide to the prescription of HA (B1). 
- As in other clinical settings, in patients with 
advanced cirrhosis, hypoalbuminaemia per se is not 
an indication for the prescription of HA (B1).
5. Evidence-based clinical indications
5.1 Prevention of post-paracentesis circulatory 
dysfunction 
5.1.1 Clinical and pathophysiological background
Paracentesis is the current first-line treatment for 
patients with tense and refractory ascites1,2. In the 
majority of patients not receiving plasma expansion, 
the removal of large volumes of ascites induces the 
development of PPCD, which is diagnosed by a 
significant increase (>50%) in plasma renin activity 
4-6 days after paracentesis14. PPCD is associated with 
a higher rate of recurrence of the ascites, dilutional 
hyponatraemia, renal impairment, re-hospitalisation, 
and poorer survival14-16.
By reducing intra-abdominal pressure, large-volume 
paracentesis boosts venous return to the heart. As a 
result, right atrial pressure decreases, while cardiac 
output and stroke volume increase. However, because 
of a paradoxically excessive drop of systemic vascular 
resistance, effective circulating volume declines further, 
leading to a reduction in arterial pressure. In the days 
after paracentesis, there is marked activation of the 
RAA axis and SNS, which persists in some cases for 
months14,15,17-19.  
5.1.2 Albumin for preventing post-paracentesis 
circulatory dysfunction 
The most effective method to prevent PPCD is to 
counteract effective hypovolaemia by using plasma-
expanders. It was first demonstrated in the 1980s that 
infusion of HA after paracentesis improves circulatory 
dysfunction and prevents the occurrence of PPCD14. 
Since the early 1990s, less costly alternatives, such 
as crystalloids and artificial colloid volume expanders, 
have been compared to HA15,20-26. When more than 5 L of 
ascites are removed, HA (6-8 g/L of ascites removed) has 
been found to more effective at preventing PPCD than the 
other plasma expanders in several studies15,20,25,26, although 
other investigations - all including very low numbers of 
patients - did not confirm this positive result21-24.
In contrast, when less than 5 L of ascites are removed, 
the incidence of PPCD is low and dextran-70 (8 g/L 
of ascites removed), polygeline (150 mL/L of ascites 
removed) or saline (150 mL/L of ascites removed) 
show an efficacy similar to that of HA15,25. However, 
polygeline is no longer used in many countries because 
of the potential risk of transmission of prions1, while 
there are concerns about the possibility that dextrans 
and starches may induce renal failure27 and accumulate 
in the liver28. Furthermore, infusion of large volumes of 
saline should be avoided in fluid-overloaded patients 
with ascites and/or peripheral oedema. 
More recently, the use of vasoconstrictors, 
including vasopressin, terlipressin, and midodrine, 
has been compared to the administration of HA after 
paracentesis29-33. However, the results of the few 
randomised clinical trials are variable, probably because 
of their very limited sample size, so that the clinical 
utility of vasopressors after paracentesis cannot be 
ascertained.
Despite this greater efficacy in preventing PPCD, 
randomised trials have not shown differences in the 
survival of patients receiving HA compared with that 
of patients given alternative treatments15,25,34. However, 
a recent meta-analysis indicates that HA after large-
volume paracentesis is significantly more effective 
than other treatments at reducing not only PPCD and 
hyponatraemia, but also mortality35. Effect sizes were 
substantial, with HA lowering the odds of PPCD by 
66%, hyponatraemia by 42%, and death by 36%. In all 
eligible trials included, the average volume of ascites 
removed was greater than 5 L and no major differences 
were apparent according to whether volumes of ascites 
removed were 5.5-8.0 L or more than 8 L. In the majority 
of studies included, the dose of HA administered per litre 
of ascites removed was 8 g, although 5 or 6 g were also 
infused in a minority of trials. 
Only one randomised trial considering HA infusion 
after large-volume paracentesis compared standard 
(8 g/L of ascites removed) versus reduced (4 g/L 
of ascites removed) doses. The incidence of PPCD, 
hyponatraemia, and renal failure were low, but similar 
in the two groups. Although, if confirmed, these 
results could support a reduction of the costs related 
to paracentesis, the small sample size again precludes 
definitive conclusions36. 
Finally, a recent health economic analysis suggested 
that HA is more cost-effective than alternative 
but cheaper plasma volume expanders since its 
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administration is associated with a lower number of 
liver-related complications within the first 30 days34.
AISF-SIMTI recommendations on the use of albumin 
to prevent post-paracentesis circulatory dysfunction
- HA should be administered after large-volume 
paracentesis exceeding 5 L at the dose of 6-8 g/L 
of ascites removed, since it reduces the incidence of 
PPCD and improves patients' clinical outcome  (A1).
- When the amount of ascites removed exceeds 5 
L, the use of alternative plasma expanders is not 
recommended because they are less effective in the 
prevention of PPCD (A1). The combined use of HA 
and other plasma expanders in order to reduce the 
dose of HA is also not recommended (D1).
- When the amount of ascites removed is less than 5 L, 
HA can be used if there are concerns regarding the 
administration of crystalloids or synthetic colloids 
(volume overload, renal failure, coagulopathy)  (B1). 
- The use of vasoconstrictors instead of HA or the 
use of reduced doses of HA should be limited to 
controlled clinical trials (C1). 
- Although there are no studies on the modalities 
of albumin administration, it seems advisable to 
infuse HA relatively slowly to avoid possible cardiac 
overload due to the existence of a latent cirrhotic 
cardiomyopathy, starting during the presumed final 
part of the paracentesis or at the end of paracentesis 
when the volume of ascites removed is known and 
the paracentesis-induced increase in cardiac output 
begins to return to baseline (D2). 
5.2 Prevention of renal failure after spontaneous 
bacterial peritonitis
5.2.1 Clinical and pathophysiological background
SBP is a life-threatening infection of ascitic fluid that 
occurs frequently in patients with advanced cirrhosis and 
requires prompt recognition and treatment. The diagnosis 
is based on the presence of >250 polymorphonuclear 
cells/mm3 of ascites, in the absence of an intra-abdominal 
source of infection or malignancy37. About one-third of 
patients with SBP develop renal impairment, which 
is often progressive irrespectively of resolution of the 
infection and is an independent predictor of in-hospital 
mortality38,39, as 42% of patients with this complication 
will die, while the mortality of those who do not develop 
renal impairment is only 7%38. 
The high incidence of renal failure after SBP is caused 
by the abrupt deterioration of circulatory function, 
involving both vascular tone and cardiac function, 
and is mediated by the marked activation of the pro-
inflammatory and vasoactive systems. While systemic 
vascular resistance remains substantially unchanged, 
possibly as a result of a striking compensatory 
activation of vasoconstrictor systems, cardiac output 
declines significantly as a consequence of chronotropic 
Table II - Summary of the panel's indications for the use of HA in patients with cirrhosis.
Clinical condition Doses and schedules 
of administration
Indications for the use of HA Quality of evidence and 
strenght of recommendation
Prevention of PPCD
Paracentesis ≥5 litres
6-8 g per litre 
of removed ascites Mandatory in all patients A1
Paracentesis <5 litres
Preferred if concerns regarding 
use of synthetic colloids 
or crystalloids 
B1
Prevention of renal 
failure after SBP High-risk patients
1.5 g/kg at diagnosis 
+ 1 g/kg on the 3rd day Mandatory in all patients A1
Low-risk patients* Consider in individual patients B1
Diagnosis of HRS 1 g/kg/die 
for 2 consecutive days To be used regularly D1
Treatment of type I HRS 
(in association with vasoconstrictors)
1 g/kg at diagnosis 
+ 20-40 g/die until 
vasoconstrictors are stopped
Mandatory in all patients A1
Long-term treatment of ascites To be defined Consider in difficult-to-treat 
ascites C1
Treatment of severe hyponatraemia To be defined Consider if no response  to 
standard measures D1
Prevention of renal failure after non-SBP bacterial 
infections
-
Not indicated at present B1
Treatment of septic shock To be defined Consider in all patients C1
Treatment of hepatic encephalopathy - Not indicated at present B1
* Low-risk patients: serum albumin <4 mg/dL and serum creatinine <1 mg/dL. 
HA: human albumin; PPCD: post-paracentesis circulatory dysfunction; HRS: hepatorenal syndrome; SBP: spontaneous bacterial peritonitis.
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incompetence and reduced myocardial contractility. 
These events ultimately lead to a marked reduction of 
effective volaemia and arterial pressure, thus impairing 
renal and, more in general, organ perfusion40. 
5.2.2 Albumin for preventing renal failure after 
spontaneous bacterial peritonitis
Administration of HA, but not hydroxyethyl starch, 
improves circulatory dysfunction in patients with 
SBP12. Along with parameters reflecting plasma volume 
expansion, other haemodynamic effects can be explained 
only recalling the non-oncotic properties of the molecule. 
In fact, the striking rise in systemic vascular resistance 
seen after HA, but not after hydroxyethyl starch 
infusion, and the concomitant significant reduction of 
the circulating levels of von Willebrand-related antigen, 
factor VIII, and nitric oxide metabolites, indicate that 
HA counteracts endothelial activation12. Furthermore, 
the improvement of stroke index supports a direct 
effect of HA on cardiac function12, as also suggested 
by the experimental finding in rats with cirrhosis and 
ascites that plasma volume expansion with HA, but not 
with hydroxyethyl starch, ameliorates left ventricular 
function ex vivo13.
The first controlled clinical trial assessing the effect 
of HA administration in patients with cirrhosis and SBP 
showed that such treatment, associated with antibiotic 
therapy, significantly reduced the incidence of renal 
failure and the in-hospital and 3-month mortality rates41. 
In more detail, 126 patients were randomised to receive 
either HA 1.5 g/kg/body weight (b.w.) at diagnosis 
and 1 g/kg b.w. on day 3 in addition to cefotaxime 
or cefotaxime alone. Although infection resolution 
rates were similar in the two groups, the incidence 
of renal impairment dropped from 33% in patients 
receiving only cefotaxime to 10% in those treated with 
cefotaxime plus HA. Baseline independent predictors 
of the development of renal impairment included serum 
bilirubin and creatinine, and treatment with cefotaxime 
alone. Confirming that the occurrence of renal failure 
in the setting of SBP carries a highly adverse prognostic 
factor, 29% of patients in the cefotaxime group died in 
hospital and 41% within 3 months. These figures were 
strikingly reduced by HA administration, as in-hospital 
and 3-months mortality rates were 10% and 22%, 
respectively. 
Post-hoc analysis showed that the incidence 
of renal impairment was higher among those with 
a baseline serum bilirubin ≥4 mg/dL (48% in the 
cefotaxime group and 12% in cefotaxime plus HA 
group) or serum creatinine ≥1 mg/dL (32% and 14%, 
respectively) than in patients with serum bilirubin <4 
mg/dL and serum creatinine < 1 mg/dL (7% and 0%, 
respectively). 
This observation raises the question of whether 
all patients with SBP need HA administration. In a 
preliminary, small study, patients with SBP at low-
risk of renal impairment (defined as bilirubin <4 
mg/dL and serum creatinine <1 mg/dL) received 
only antibiotic treatment and none developed renal 
impairment or died42. In a more recent retrospective 
study43, episodes of "low-risk" SBP were associated 
with a much lower incidence of renal failure as well 
as lower in-hospital and 3-month mortality rates 
compared with "high-risk" episodes (4.7%, 3.1% 
and 7% vs 25.6%, 38.2% and 47%, respectively). 
Among the latter, those treated with HA had a lower 
in-hospital mortality than those treated only with 
antibiotics (28.8% vs 46.8%) and a higher probability 
of survival at 3 months (62% vs 45%). Thus, HA 
administration clearly improves the survival of 
patients with high-risk SBP, but it does not seem to 
be necessary for patients with low-risk SBP. However, 
this conclusion awaits confirmation in a randomised, 
prospective study.
Similarly, confirmation is also needed for the results 
of a pilot study that assessed whether a lower dose of 
HA could be used44. In the pilot study, a reduced dose 
regimen (1.0 g/kg b.w. at diagnosis and 0.5 g/kg b.w. on 
day 3) appeared to be as effective as the standard regimen 
in preventing renal failure in a group of cirrhotic patients 
with SBP including 77% at "high-risk". In-hospital (27% 
vs 21%) and 3-month mortality (36% vs 37%) rates also 
did not differ between patients receiving the reduced or 
the standard HA dose, respectively.
Finally, a recent meta-analysis of randomised trials 
substantially confirmed that HA infusion prevents renal 
impairment and reduces mortality among patients with 
SBP45. However, there is still limited evidence available 
on the outcomes of patients with low-risk SBP who do 
not receive HA as well as on the responsiveness of low-
risk patients to HA infusion.
AISF-SIMTI recommendations on the use of albumin 
to prevent renal failure after spontaneous bacterial 
peritonitis
- HA (1.5 g/kg/b.w. at diagnosis and 1 g/kg/b.w. on 
day 3) should be administered, in association with 
antibiotic therapy, in cirrhotic patients with SBP 
since this approach reduces the incidence of renal 
failure and improves survival (A1). 
- Patients with baseline serum bilirubin <4 mg/dL 
and serum creatinine <1 mg/dL have a low risk of 
developing renal failure after SBP. In this group of 
patients the benefit of HA is unclear and the decision 
to administer HA should be individualised (B1).
- The use of crystalloids and synthetic colloids instead of 
HA or in association to HA is not recommended (D1).
15
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- The use of reduced doses of HA should be limited to 
controlled clinical trials (Level C1).
5.3 Diagnosis and treatment of hepatorenal syndrome
5.3.1 Clinical and pathophysiological background
HRS is defined as the occurrence of renal failure 
in patients with advanced liver disease without 
another, identifiable cause46-48. Type 1 HRS is a rapidly 
progressive acute renal failure that frequently develops 
in temporal relationship with a precipitating factor, such 
as a bacterial infection. Its prognosis is dismal since the 
median survival without treatment is approximately 2 
weeks. Type 2 HRS occurs in patients with refractory 
ascites and is characterised by a moderate, slowly 
progressive degree of functional renal failure, often with 
avid sodium retention. Patients with type 2 HRS may 
eventually develop type 1 HRS either spontaneously or 
following a precipitating event, such as SBP46,47. 
Marked renal arterial vasoconstriction is the main 
pathophysiological feature of type 1 HRS. It develops 
in the context of a severe reduction of the effective 
circulating volume, which is related both to splanchnic 
arterial vasodilation and to an inadequate cardiac output, 
leading to extreme over-activation of the endogenous 
vasoconstrictor and sodium-retaining systems (RAA, 
SNS, and ADH)47,49. 
5.3.2 Albumin for the diagnosis 
The diagnosis of HRS is one of exclusion. Besides 
excluding organic causes, the diagnosis is based on 
the lack of response to volume expansion in order to 
differentiate HRS from other forms of functional renal 
failure46-48. No studies have been performed to establish 
whether plasma volume expansion should be performed 
with HA rather than saline. Members of the panel of the 
International Club of Ascites have agreed that HA causes 
a greater and more sustained expansion than saline47,48, 
as it can be assumed by the studies on PPCD showing 
the superiority of HA over saline or synthetic colloids.
5.3.3 Albumin for the treatment of type 1 hepatorenal 
syndrome
Most of the existing information on treatment of 
HRS is related to patients with type 1 HRS. Therefore, 
all the following comments refer to type 1 HRS unless 
otherwise specified. Once diagnosed, treatment should 
be started early in order to prevent the progression of 
renal failure. 
The most effective treatment of HRS currently 
available is the administration of vasoconstrictor drugs 
together with HA. Terlipressin, a vasopressin analogue 
acting on V1 receptors, mainly located in the splanchnic 
area, is the most studied vasoconstrictor. It improves 
the markedly impaired circulatory function by causing 
vasoconstriction of the extremely dilated splanchnic 
vascular bed, thus increasing mean arterial pressure and 
renal perfusion50. In most studies, terlipressin was given 
in combination with HA in order to further improve 
the effective circulating volume. Interestingly, when 
terlipressin has been used without HA, treatment was 
considerably less effective51.
Several randomised52-56 and non-randomised51,57,58 
clinical trials have shown that terlipressin and HA 
improve renal function and that full reversal of type 1 
HRS is obtained in up to 40-50% of patients. Although 
responders survive longer than non-responders, the 
overall survival was not significantly superior in patients 
receiving terlipressin plus HA than in those treated with 
HA alone or placebo52,53,57. Nevertheless, a recent meta-
analysis showed that the combined treatment is also able 
to improve short-term survival59. 
HA is given at the initial dose of 1 g/kg.b.w. on day 
1, followed by 20-40 g/day according to the central 
venous pressure and/or evidence of volume overload 
until terlipressin is stopped52,53. 
A few studies have evaluated other vasoconstrictors 
for the management of type 1 HRS, such as noradrenaline, 
which showed a similar efficacy as terlipressin60,61, and 
midodrine plus octreotide, a combination that was 
less effective than terlipressin62. With both treatment 
approaches, HA is given at the doses described for use 
with terlipressin60-62.
Information on the use of vasoconstrictors plus HA 
in patients with type 2 HRS is really limited. Although 
the combined treatment improves renal function63,64, 
the rate of HRS recurrence after treatment withdrawal 
appears to be very high. 
AISF-SIMTI recommendations on the use of albumin 
in the diagnosis and treatment of hepatorenal syndrome
- HA administration (1 g/kg/b.w. for two consecutive 
days) should be used to expand plasma volume for 
the differential diagnosis of HRS (D1). 
- HA should be given with terlipressin in patients 
with type 1 HRS at the dose of 1 g/kg/b.w. on day 
1 followed by 20-40 g per day until terlipressin is 
withdrawn (A1). When possible, the HA dose should 
be titrated according to the level of the central venous 
pressure. Alternatively, HA should be reduced or 
stopped in the presence of clinical evidence of volume 
overload and/or pulmonary oedema (A1).
- HA should be given with other vasoconstrictors 
(noradrenaline or midodrine plus octreotide) in 
patients with type 1 HRS at the same doses as used 
with terlipressin (A1).
- If patients with type 2 HRS are treated with 
vasoconstrictors, HA should be added according to 
the dosages used in type 1 HRS (B1).
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6. Non-evidence-based clinical indications
6.1 Long-term treatment of cirrhotic ascites
6.1.1 Clinical and pathophysiological background
Ascites is the most frequent complication of liver 
cirrhosis, occurring in more than 50% of patients 
within 10 years of the diagnosis, and is associated 
with a significant worsening of the prognosis65,66. 
Medical treatment of uncomplicated ascites is based 
on diuretics associated to a mild reduction of dietary 
sodium intake65,66. Approximately 10% of patients 
per year develop refractory ascites, as defined by the 
International Club of Ascites, either because of a lack of 
response to medical treatment or because of the onset of 
diuretic-induced complications that preclude the use of 
an effective dosage of these drugs65,67. Refractory ascites 
is associated with an increased incidence of severe 
complications of cirrhosis, such as HRS, hyponatraemia, 
SBP, and umbilical hernia rupture and strangulation. 
Thus, the overall probability of survival of patients with 
refractory ascites is very poor, being approximately 30% 
at 2 years65-67. 
Renal sodium retention and ascites formation are 
consequences of effective hypovolaemia, resulting from 
arteriolar vasodilation mainly in the splanchnic area, 
which promotes vasoconstriction and renal retention of 
sodium and water through the compensatory activation 
of neuro-humoral systems (RAA, SNS, ADH) and, in 
the more advanced stage of cirrhosis, through reduced 
renal perfusion66.
Thus, preservation of the central blood volume 
represents a potential target in the management of ascites.
6.1.2 Albumin for the long-term treatment of ascites
The use of HA for the treatment of ascites is 
allowed within the Italian National Health Service, 
but reimbursement for out-of-hospital prescriptions is 
limited to patients with ascites not responding to standard 
diuretic therapy (Note 15 of the Italian Medicines 
Agency). However, the long-term administration of 
HA to treat ascites is still debated, because of the lack 
of definitive scientific evidence supporting its clinical 
benefit. 
Apart from a few reports of uncontrolled small 
studies and sporadic cases from more than a half 
century ago, only two randomised clinical trials from 
an Italian group have been published so far68,69. In 1999, 
two groups of hospitalized patients with cirrhosis and 
ascites were randomised to receive diuretics, given in 
a stepwise response-guided schedule, with or without 
daily infusion of 12.5 g HA during hospitalisation 
(median duration >20 days) followed by 25 g/week 
after discharge (median follow-up >20 months)68. 
The treatment with diuretics plus HA was overall 
more effective than diuretics alone in resolving 
ascites during hospitalisation and reducing the time 
the patients stayed in hospital. However, these results 
were achieved only in the subset of patients receiving 
low-dose diuretics (25 mg/day furosemide and 200 mg/
day potassium canrenoate), while the advantage was 
lost when the anti-aldosteronic drug was used alone 
or when higher doses of diuretics were needed. No 
effect on survival after discharge was seen68. Despite 
the positive results, it is hard to transfer these regimens 
into current clinical practice in which these patients are 
managed as outpatients. 
In a subsequent study69, a cohort of 100 patients was 
randomised to receive chronic treatment with either 
diuretics alone or diuretics plus HA (25 g/week for the 
first year, then 25 g every 2 weeks) (median follow 
>84 months). The recurrence rate of moderate to severe 
ascites and mortality were significantly lower in patients 
who received the supplemental HA. However, the 
relatively small sample size prevents firm conclusions 
from being reached.
No other controlled clinical trials have been performed 
so far to evaluate the effectiveness of prolonged HA 
administration in the treatment of cirrhosis and ascites. 
The lack of confirmatory randomised studies, together 
with the high cost of this therapeutic strategy, explain 
why long-term chronic HA infusion is not endorsed by 
international guidelines1,2 and it is, therefore, not usually 
included among therapeutic options for difficult-to-treat 
ascites in countries other than Italy. 
A definite solution to this controversial issue will 
be provided by an open-label, multicentre, randomised, 
no-profit clinical trial, currently underway in Italy. 
This trial, supported by the Italian Medicines Agency, 
is comparing the effectiveness of long-term weekly 
administration of HA (40 g twice a week for the first 
2 weeks and 40 g once a week for a maximum of 18 
months independently of the serum albumin level) in 
420 patients with cirrhosis and uncomplicated ascites 
receiving at least 200 mg per day of an anti-aldosteronic 
drug and 25 furosemide per day (ANSWER study, NCT 
01288794, www.clinicaltrials.gov). The preliminary 
results from 386 patients were recently presented 
in abstract form70, showing that patients treated 
with diuretics plus HA required significantly fewer 
paracenteses and had lower incidences of refractory 
ascites as well as SBP, renal impairment, and hepatic 
encephalopathy. 
Thus, although increasing evidence supports 
the benefit of HA in improving the management 
of ascites and the clinical outcome of patients with 
decompensated cirrhosis, the final results of the 
ANSWER study are eagerly awaited to confirm the 
efficacy of long-term administration of HA for this 
indication.
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AISF-SIMTI recommendations on the long-term use 
of albumin to treat ascites 
- Long-term HA can be effective in the treatment 
of ascites in association with diuretics (C1). The 
efficacy, dosage and timing of HA administration need 
to be defined by adequately-powered randomised 
controlled trials.
6.2 Treatment of hyponatraemia
6.2.1 Clinical and pathophysiological background
Hyponatraemia is a common finding in patients 
with cirrhosis and is characterised by low serum 
sodium levels (<135 mmol/L) usually associated with 
the presence of ascites, often refractory, and peripheral 
oedema. It is caused mainly by impaired solute-free 
water excretion secondary to hypersecretion of ADH, 
which is stimulated by effective hypovolaemia and 
results in a disproportionate retention of water relative 
to sodium retention71,72. 
Besides the fact that serum sodium concentration 
is an important marker of prognosis in cirrhosis71,73, 
hyponatremia, mostly when severe (<125 mmol/L), can 
induce neurological complications per se or precipitate 
hepatic encephalopathy and is associated with reduced 
survival after liver transplantation74,75. 
6.2.2 Albumin for the treatment of hyponatraemia
It is generally considered that management of 
hyponatremia should be started when the serum sodium 
concentration is lower than 130 mmol/L and includes 
fluid restriction, withdrawal of diuretics, and infusion of 
hypertonic saline solution although this latter approach 
is still controversial1. 
B a s e d  o n  a  s t r o n g  p a t h o p h y s i o l o g i c a l 
rationale to use HA, that is blunting the non-
osmotic hypersecretion of ADH through the 
improvement of effective hypovolaemia, many 
hepatologists consider HA an effective treatment 
for hyponatraemia. However, no randomised 
trials directly assessing the efficacy of HA have 
been published in extenso. Apart from a positive 
report on a few isolated cases76, the results of a 
small randomised trial, published in 2007 only in 
abstract form, showed that the administration of HA 
improves serum sodium concentration77. 
AISF-SIMTI recommendations on the use of albumin 
to treat hyponatraemia
- Based on the pathophysiological background, 
HA might  be  e f fec t ive  to  correct  severe 
hyponatraemia not responding to standard 
measures, particularly in patients with symptoms 
related to hyponatraemia or waiting for liver 
transplantation (D1). 
7. Clinical indications under investigations
7.1 Prevention of renal failure after bacterial 
infections other than spontaneous bacterial 
peritonitis
7.1.1 Clinical and pathophysiological background
Renal failure also frequently occurs in patients with 
bacterial infections other than SBP. In one study that 
enrolled 106 consecutive patients with cirrhosis and 
sepsis unrelated to SBP78, renal impairment developed in 
27% of cases compared with only 8% in those without 
sepsis. The infections that most often led to renal failure 
were culture-negative sepsis (66%) and spontaneous 
bacteraemia (45%), followed by cellulitis, pneumonia 
and urinary tract infections. Unlike the situation with SBP, 
however, reversible renal impairment prevailed (76%), 
with the proportion not being substantially different from 
that found in patients without sepsis (62%). 
As in SBP, the development of renal impairment 
strongly influences the outcome of patients with non-
SBP bacterial infections, as 43% of these patients who 
developed renal impairment died in hospital79 and 66% 
within 3 months78, which are far higher percentages than 
those in patients who did not develop renal impairment 
(7% and 13%, respectively). 
7.1.2 Albumin for the treatment of bacterial infections 
other than spontaneous bacterial peritonitis
Whether HA administration can be beneficial for non-
SBP bacterial infections is still under investigation. The 
first published randomised trial on this issue80 enrolled 
110 patients affected by pneumonia, urinary tract or skin 
infections, or culture-positive bacteraemia; however, 
in 20% of patients, infection was only suspected. 
The patients were randomised to receive appropriate 
antibiotic treatment alone or antibiotic treatment plus HA 
at the "standard" dose regimen used for SBP. Although 
both renal function (evaluated by serum creatinine and 
estimated glomerular filtration rate) and circulatory 
function (assessed by plasma renin activity, plasma 
aldosterone concentration, noradrenaline level, and 
mean arterial pressure) improved in patients receiving 
HA, the occurrence of type 1 HRS and the 3-month 
mortality rate did not differ between the two groups. 
However, multivariate analysis showed that treatment 
with HA was an independent predictive factor of survival 
when groups were adjusted according to the other 
predictors of survival, with a 3.4 relative risk of death 
for patients receiving only antibiotics. 
A more recent French multicentre, randomised trial81 
enrolled 193 cirrhotic patients with a Child-Pugh score 
greater than 8 and sepsis unrelated to SBP to receive 
antibiotics plus HA (1.5 g/kg on day 1 and 1 g/kg on 
day 3) or antibiotics alone. HA infusion delayed the 
occurrence of renal failure (mean time to onset: 29±22 
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vs 12±9 days, p=0.018), but the 3-month survival and 
renal failure rate were similar (70.2 vs 78.3% and 14.3 
vs 13.5%, respectively). Post-hoc analysis showed a 
trend toward a better survival in patients with ascites and 
severe circulatory dysfunction. Interestingly, pulmonary 
oedema developed in about 8% of patients receiving HA.
Thus, HA administration appears to produce some 
benefit only in selected patients with bacterial infections, 
i.e. those patients at high risk of renal failure and death, 
but further studies are needed to confirm this conclusion. 
An ongoing large, multicentre European randomised 
trial (INFECIR-2 study, ClinicalTrials.gov, Identifier: 
NTC02034279) has been started by the EASL Chronic 
Liver Failure Consortium with the aim of assessing the 
effect of HA administration in high-risk patients with 
non-SBP bacterial infections, as defined by the presence 
of liver and kidney impairment, parameters of systemic 
inflammatory response syndrome (SIRS), and type of 
infection.
AISF-SIMTI recommendations on the use of albumin 
for the prevention of renal failure after bacterial 
infections other than spontaneous bacterial peritonitis 
- HA administration, in association with antibiotics, 
is not currently indicated in patients with cirrhosis 
and bacterial infections other than SBP (B1).
7.2 Treatment of septic shock
Patients with septic shock have shown improved 
survival with early goal-directed therapy, based on the 
combination of empirical antibiotics, vasoconstrictors, 
and volume replacement82. Regarding this last, there 
are not specific studies evaluating the administration 
of HA in cirrhotic patients with septic shock. However, 
some data can be extrapolated from large randomised 
trials comparing crystalloids with HA in the general 
population. In a subgroup of 1,218 patients with severe 
sepsis enrolled in the SAFE study, multivariate analysis 
revealed that those receiving HA had a lower risk of 
death at day 28 as compared to those receiving saline 
(adjusted odd ratio: 0.71)83. Furthermore, a meta-analysis 
comparing HA and crystalloids in septic patients showed 
a survival benefit with HA84. This positive result was 
very recently challenged by a randomised trial (the 
ALBIOS study), including nearly 2,000 patients with 
severe sepsis enrolled in about 100 Italian Intensive Care 
Units, showing that HA administration did not improve 
28-day and 90-day survival rates compared to those 
achieved with administration of crystalloids. However, 
according to a subgroup post-hoc analysis, a benefit of 
HA was found in patients with septic shock85.
Although only a few patients with cirrhosis were 
enrolled in these trials and the results should not, 
therefore, be transferred automatically to the setting 
of cirrhosis, some considerations favour the use of 
HA in patients with cirrhosis and septic shock. First, 
expansion with saline or Ringer's lactate solution 
requires infusion of high volumes of fluids, which can 
be detrimental because they can worsen ascites and 
oedema. Moreover, the use of low-molecular-weight 
hydroxyethyl starch solutions raises concerns because 
of an increased risk of kidney and liver injury27,28. 
Finally, a specific benefit of HA may also derive 
from the non-oncotic properties of the molecule since 
these can antagonise some of the pathophysiological 
mechanisms related to septic shock6.
AISF-SIMTI recommendations on the use of albumin 
in the treatment of septic shock in patients with 
cirrhosis 
- HA solutions might be effective and safe in cirrhotic 
patients with septic shock (C1). 
7.3 Treatment of hepatic encephalopathy
7.3.1 Clinical and pathophysiological background
Hepatic encephalopathy is characterised by an 
acute change in mental status, frequently induced by 
a precipitating event, such as constipation, severe 
infection, gastrointestinal bleeding, renal failure 
or acute liver injury. It is a major complication of 
cirrhosis, being associated with high mortality, poor 
quality of life, and a high risk of recurrence85. The 
underlying pathophysiological mechanisms include 
over-exposure of the brain to plasma ammonia and 
other toxins escaping from the splanchnic circulation 
and the activation of inflammatory mediators, including 
oxidative stress, which induce swelling of astrocytes 
and disturb neurotransmission85. The treatment of 
hepatic encephalopathy is based mainly on correcting 
precipitating factors and reducing ammonia absorption86.
7.3.2 Albumin for the treatment of  hepatic 
encephalopathy
Administration of HA may reduce oxidative stress-
mediated injury and improve hepatic encephalopathy. 
However, so far, only one randomised clinical trial on 
this issue has been published: in this trial, the efficacy 
of HA was assessed in 56 patients with episodic grade 
II-IV hepatic encephalopathy, stratified according the 
severity of the encephalopathy87. The addition of HA (1.5 
g/kg on the first day and 1 g/kg after 48 h) to the current 
standard management did not improve the resolution 
of the encephalopathy during hospitalisation, although 
treatment with HA was found to be an independent 
predictor of 90-day transplant-free survival. 
Very recently, a small study found no differences 
in the incidence of overt hepatic encephalopathy after 
placement of a transjugular intrahepatic porto-systemic 
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shunt (TIPS) between a group of patients treated with 
HA and historical controls during the first month (34 vs 
31 %) or during the follow-up (39 vs 48 %)88.
AISF-SIMTI recommendations on the use of albumin 
in the treatment of hepatic encephalopathy 
- Administration of HA is not currently indicated for 
the treatment of hepatic encephalopathy (B1).
8. The prescription of albumin in Italy
Studies and surveys in different countries have 
consistently reported that many HA prescriptions, 
ranging from 40% up to 90%, are not supported by clinical 
evidence, guidelines or practical recommendations89-92. 
Most of the inappropriate prescriptions derive from 
the use for nutritional interventions or for correcting 
hypoalbuminaemia per se (without hypovolaemia), 
which still occurs in many clinical areas (e.g. surgery, 
internal medicine, geriatrics, oncology), despite the 
existence of solid data against a real benefit. Other 
clinical uses for HA administration not supported 
by solid scientific evidence are nephrotic syndrome, 
pancreatitis, abdominal surgery, acute respiratory 
distress syndrome, cerebral ischaemia, and enteric 
disease89-92.
The Italian consumption of HA from 2007 to 2011 
was analysed in the first Italian report on the prescription 
of plasma-derived medicinal product93,94.  
The total demand for HA remained substantially 
stable in the above 5-year period, decreasing only 
minimally (-1%) from 36,652,396 g in 2007 to 
36,442,660 g in 2011. A similar trend (-3%) was 
maintained when HA consumption was standardised 
per population, going from 620 g per 1,000 residents in 
2007 to 601 g per 1,000 residents in 201195. This trend 
was evident in all the Italian regions, with the exception 
of Valle d'Aosta, Umbria, and Lombardy, where the 
standardied consumption increased considerably (+57%, 
+54%, and +25%, respectively). 
The differences in the amount of prescribed HA 
among the Italian regions are quite remarkable. The five 
regions with the highest HA standardised consumption 
were Sardinia, Puglia, Campania, Calabria, and Lazio, 
with levels of 103%, 53%, 23%, 21%, and 17% above 
the Italian mean, respectively. It is important to note that 
these five regions account for 28% of the total Italian 
consumption although their combined population is 
19.1% of the total Italian population.  On the other hand, 
the five-lowest standardised HA demands were recorded 
in Bolzano, Trento, Friuli-Venezia Giulia, Marche, and 
Piedmont, being 62%, 61%, 54%, 39%, and 38% lower 
than the national mean level, respectively96.
HA consumption also appears to be greatly influenced 
by the channel of HA distribution (pharmacies open to 
the public, public healthcare system, private healthcare 
facilities)94. 
Most HA was distributed through the public 
healthcare system with a mean national amount of 422 
g per 1,000 residents. This channel of distribution was 
particularly predominant in Sardinia and Tuscany (157% 
and 49% above the mean national level, respectively).
The mean national level of HA distributed by 
pharmacies open to the public was 83 g per 1,000 
residents in 2011. However, this channel of distribution 
was much more substantial in Campania, Puglia and 
Calabria, accounting for 270, 262, and 231 g per 1,000 
residents, respectively. These three regions showed 
really remarkable deviations above the national 
mean level of 324%, 314%, and 277%, respectively. 
Furthermore, these are among the Italian regions with 
the highest standardised HA consumption. 
As far as the distribution by private healthcare 
facilities is concerned, the mean national value in 2011 
was 67 g per 1,000 residents. Conspicuous use was 
reported in Lazio, Molise and Lombardy, where private 
hospitals account for a significant part of the healthcare 
organisation; in these three regions the deviation above 
the national mean value was 153%, 128%, and 68%, 
respectively.
Finally, benchmarking national data shows that the 
2011 standardised HA consumption per 1000 residents 
was several times higher in Italy (601 g) than in other 
European countries of comparable socio-economic level, 
such as France (238 g), Germany (148 g), and the United 
Kingdom (82 g)96.
Unfortunately, this report lacks data regarding 
the clinical indications for the HA prescriptions, thus 
precluding an analysis of appropriateness. However, 
although the very high prevalence of cirrhosis, 
particularly in the Southern regions, may at least in 
part explain the above described differences, all these 
data together suggest that there is substantial room for 
improving the appropriate use of HA.
Besides the large proportion of inappropriate use, 
the high cost, theoretical risk of disease transmission 
and existence of more economic alternatives of 
comparable efficacy have prompted interventions 
aiming at rationalising and rendering more appropriate 
the use of HA89-91. In this regard, a recent report 
from an Italian academic hospital showed that the 
enforcement of in-hospital guidelines produced two 
major consequences: first, the increasing trend observed 
before implementation of the recommendations was 
interrupted and HA consumption dropped about 15% 
remaining stable in the following years; second, a 
more liberal use of HA was guaranteed for indications 
supported by solid scientific data, while its futile 
administration in settings in which there is a lack of 
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clinical evidence of efficacy was avoided. This more 
appropriate prescription of HA was achieved while 
maintaining health care expenditure under control97.
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